Shantha Bio launches JE vaccine

Hyderabad-based Shantha Biotechnics, one of the prominent players in the modern biotech products for healthcare, has launched Jencevac, a vaccine for combating Japanese Encephalitis (commonly known as brain fever) in the domestic market.

Shantha Biotech has entered into a partnership with Korea-based Green Cross Vaccine Corporation for the distribution and marketing of Jencevac in India.

Green Cross is an international pharmaceutical company which aims at providing prophylactic vaccines that are of high quality, safe and affordable across the globe, according to a press release.

Japanese Encephalitis "� the most epidemic and viral encephalitis "� is an inflammation of the brain, which is a reaction of the body's immune system to infection or invasion.

The viruses live in animal hosts and mosquitoes that transmit the disease to humans, often leading to permanent mental disability and sometimes death.

Commenting on the launch, Varaprasad Reddy, managing director of Shantha Biotechnics, said, "Jencevac is produced using the inactivated Nakayama strain known for its good propagation characteristics and its strength to provide cross-protection against other Japanese Encephalitis (JE) viral strains. With Jencevac, Shantha reiterates its dedication of providing excellent human healthcare products at affordable prices matched with good quality. JE vaccine is yet another step we have taken forward for fulfilling our mission of creating a healthy and ailment-free society."